BCDA Logo

BioCardia, Inc. (BCDA) 

NASDAQ
Market Cap
$10.52M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
320 of 775
Rank in Industry
190 of 433

Largest Insider Buys in Sector

BCDA Stock Price History Chart

BCDA Stock Performance

About BioCardia, Inc.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the …

Insider Activity of BioCardia, Inc.

Over the last 12 months, insiders at BioCardia, Inc. have bought $2,525 and sold $55,815 worth of BioCardia, Inc. stock.

On average, over the past 5 years, insiders at BioCardia, Inc. have bought $496,306 and sold $55,815 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Altman Peter (President and CEO) — $2,525.

The last purchase of 1,350 shares for transaction amount of $2,525 was made by Altman Peter (President and CEO) on 2024‑11‑15.

List of Insider Buy and Sell Transactions, BioCardia, Inc.

2024-11-15PurchasePresident and CEO
1,350
0.034%
$1.87$2,525+11.35%
2024-01-19Sale10 percent owner
129,802
0.5902%
$0.43$55,815-27.21%
2023-08-17PurchasePresident and CEO
4,000
0.0199%
$0.87$3,484-52.24%
2023-08-14PurchasePresident and CEO
4,500
0.022%
$0.88$3,978-53.88%
2023-05-26PurchasePresident and CEO
6,200
0.0264%
$1.60$9,920-75.30%
2022-12-16Purchasedirector
595,238
3.3%
$1.68$1,000,000+9.94%
2022-11-11PurchasePresident and CEO
1,400
0.0079%
$1.86$2,604+1.89%
2022-11-10PurchasePresident and CEO
3,100
0.0176%
$1.87$5,797+1.08%
2022-10-10PurchaseChief Financial Officer
2,000
0.0112%
$2.07$4,140-4.75%
2022-09-23PurchasePresident and CEO
1,400
0.0079%
$1.87$2,618+6.99%
2022-09-22PurchasePresident and CEO
3,100
0.017%
$1.81$5,611+7.57%
2022-09-21PurchasePresident and CEO
2,750
0.0163%
$1.92$5,280+9.34%
2022-01-11PurchasePresident and CEO
100
0.0006%
$1.87$187-2.14%
2020-06-19Purchasedirector
142,850
1.6989%
$2.10$299,985+44.98%
2020-06-19Purchasedirector, 10 percent owner
142,850
1.6989%
$2.10$299,985+44.98%
2020-06-19Purchasedirector
142,850
1.6989%
$2.10$299,985+44.98%
2020-03-24PurchasePresident and CEO
1,200
0.0185%
$2.90$3,480+3.09%
2020-03-19PurchasePresident and CEO
400
0.0058%
$2.95$1,180-6.52%
2020-03-18PurchasePresident and CEO
3,300
0.0555%
$2.53$8,349+27.05%
2020-03-17PurchasePresident and CEO
200
0.0037%
$3.66$732-4.64%

Insider Historical Profitability

2.02%
FROST PHILLIP MD ET AL10 percent owner
1896025
41.3592%
$2.29192+9.94%
Altman PeterPresident and CEO
105331
2.2977%
$2.29620<0.0001%
Brooks Andrew ACEO
63560031
1386.475%
$2.29110
BROOKS JONATHANdirector, 10 percent owner
32045292
699.0241%
$2.2912
Allen Jim L.director
668200
14.5759%
$2.2910+44.98%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.